1448232-80-1

Basic information

• Product Name: Naquotinib
• Synonyms: Naquotinib;ASP-8273;6-Ethyl-3-[[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[[(3R)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]oxy]-2-pyrazinecarboxamide;(R)-5-((1-acryloylpyrrolidin-3-yl)oxy)-6-ethyl-3-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrazine-2-carboxamide;Naquotinib,ASP-8273
• CAS NO: 1448232-80-1
• Molecular Formula: C30H42N8O3
• Molecular Weight: 562.70628
• EINECS: -0
• Mol File: 1448232-80-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 717.6±60.0 °C(Predicted)
• Appearance: /
• Density: 1.248±0.06 g/cm3(Predicted)
• PKA: 14.10±0.50(Predicted)
• CAS DataBase Reference: Naquotinib(CAS DataBase Reference)
• NIST Chemistry Reference: Naquotinib(1448232-80-1)
• EPA Substance Registry System: Naquotinib(1448232-80-1)

Safety Data

• Hazardous Substances Data: 1448232-80-1(Hazardous Substances Data)

Usage

General Description

Naquotinib is a chemical compound currently being studied and developed as a potential treatment for various forms of cancer. As a third-generation inhibitor, this substance specifically targets certain non-small cell lung cancers. The chemical demonstrates a high potential to selectively inhibit EGFR tyrosine kinase, including those that resist traditional treatments due to the presence of T790M and C797S mutations. However, like any potential treatment, it is still undergoing rigorous testing and clinical trials to assess its safety, efficacy, and potential side effects.

Relevant articles and documents

PYRAZINECARBOXAMIDE COMPOUND

[Problem] A compound which is useful as an inhibitor on EGFR T790M mutation kinase activity is provided. [Means for Solution] The present inventors have investigated a compound having an inhibitory action on an EGFR T790M mutation kinase, and have found that a pyrazinecarboxamide compound has an inhibitory action on an EGFR T790M mutation kinase, thereby completing the present invention. The pyrazinecarboxamide compound of the present invention has an inhibitory action on an EGFR T790M mutation kinase, and can be used as an agent for preventing and/or treating EGFR T790M mutation positive cancer, in another embodiment, EGFR T790M mutation positive lung cancer, in a still other embodiment, EGFR T790M mutation positive non-small cell lung cancer, in further still another embodiment, EGFR T790M mutation protein positive cancer, in further still another embodiment, EGFR T790M mutation protein positive lung cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant lung cancer, and in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer, or the like.